At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NUVB Nuvation Bio, Inc.
Trading 02-09 10:17:13 EST
5.58
-0.12
-2.19%
High5.92Low5.31Vol831.15K
Open5.82D1 Closing5.70Amplitude10.67%
Mkt Cap1.91BTradable Cap1.29BTotal Shares342.83M
T/O4.60MT/O Rate0.36%Tradable Shares231.05M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nuvation Bio Finalizes Protocol Amendment to Change Safusidenib Study From Mid-Stage to Late-Stage Trial
MT Newswires Live  ·  22:04
Nuvation Bio Finalizes Protocol Amendment to Change Safusidenib Study From Mid-Stage to Late-Stage Trial
Nuvation Bio Launches Phase 3 SIGMA Trial of Safusidenib for IDH1-Mutant Glioma
Reuters  ·  21:00
Nuvation Bio Launches Phase 3 SIGMA Trial of Safusidenib for IDH1-Mutant Glioma
Nuvation Bio Announces Pivotal Global Phase 3 Sigma Trial (G203) for Safusidenib in Idh1-Mutant Glioma
THOMSON REUTERS  ·  21:00
Nuvation Bio Announces Pivotal Global Phase 3 Sigma Trial (G203) for Safusidenib in Idh1-Mutant Glioma
Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement
Simply Wall St.  ·  01-25
Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement
JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)
TIPRANKS  ·  01-23
JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB)
RBC Raises Price Target on Nuvation Bio to $12 From $9, Keeps Outperform, Speculative Risk
MT Newswires Live  ·  01-21
RBC Raises Price Target on Nuvation Bio to $12 From $9, Keeps Outperform, Speculative Risk
Wedbush Remains a Buy on Nuvation Bio (NUVB)
TIPRANKS  ·  01-13
Wedbush Remains a Buy on Nuvation Bio (NUVB)
Nuvation Bio shares attractive on weakness, says B. Riley
TIPRANKS  ·  01-13
Nuvation Bio shares attractive on weakness, says B. Riley
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB), Mediwound (MDWD) and Argenx Se (ARGX)
TIPRANKS  ·  01-13
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB), Mediwound (MDWD) and Argenx Se (ARGX)
Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment
Dow Jones  ·  01-13
Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment
Nuvation Bio falls -17.3%
TIPRANKS  ·  01-12
Nuvation Bio falls -17.3%
Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright
TIPRANKS  ·  01-12
Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright
Nuvation Bio Inc. : H.c. Wainwright Cuts Target Price to $17 From $18
THOMSON REUTERS  ·  01-12
Nuvation Bio Inc. : H.c. Wainwright Cuts Target Price to $17 From $18
Nuvation Bio Inc. Highlights Oncology Pipeline and Global Strategy in New Corporate Presentation
Reuters  ·  01-12
Nuvation Bio Inc. Highlights Oncology Pipeline and Global Strategy in New Corporate Presentation
Nuvation Bio, Eisai enter exclusive taletrectinib license agreement
TIPRANKS  ·  01-12
Nuvation Bio, Eisai enter exclusive taletrectinib license agreement
Press Release: Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
Dow Jones  ·  01-12
Press Release: Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
Nuvation Bio Inc - Prelim Ibtrozi Net Product Revenue $15.7 Mln in Q4
THOMSON REUTERS  ·  01-12
Nuvation Bio Inc - Prelim Ibtrozi Net Product Revenue $15.7 Mln in Q4
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Reuters  ·  01-12
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Nuvation Bio Signs Exclusive Licensing Agreement with Eisai for Taletrectinib
Reuters  ·  01-12
Nuvation Bio Signs Exclusive Licensing Agreement with Eisai for Taletrectinib
Nuvation Bio Inc: Maa for Treatment of Advanced Ros1+ Nsclc Is Expected to Be Filed in Europe in First Half of 2026
THOMSON REUTERS  ·  01-12
Nuvation Bio Inc: Maa for Treatment of Advanced Ros1+ Nsclc Is Expected to Be Filed in Europe in First Half of 2026

Introduction

Company Name.
Nuvation Bio, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .
Issue price:
--